On the evening of May 26, the pre-disclosure information of the website of the China Securities Regulatory Commission showed that medical device manufacturer Shenzhen Mindray Biomedical Electronics Co., Ltd. (hereinafter referred to as Mindray Medical ) issued the initial public offering prospectus, and the company plans to list on the Shenzhen Stock Exchange. The issuance does not exceed 121.6 million shares, accounting for no less than 10% of the total share capital after the issuance, and the proposed fund raising is about 6.626 billion yuan. The reporter noted that in addition to the founders of Mindray Medical, Li Xiting and Xu Hang jointly held 64.6263% of the company's shares indirectly, including Shenzhen Gao Tejia, Taikang Insurance, Kunshan Bank of China Investment, Shanghai Guojun Venture Capital, Hangzhou Pioneer Cornerstone. Nearly 40 institutions hold shares. Nearly 40 institutions hold shares According to public information, Mindray Medical was listed on the US stock market in September 2006. After one year, the stock price rose to a historical peak of US$44.99 per share. However, although Mindray's annual revenue and profit have maintained steady growth, Mindray's market capitalization has remained at around $3.2 billion, with a price-to-earnings ratio of 18 times. In June 2015, Mindray Medical announced the start of the privatization process. On March 6, last year, Mindray Medical announced that it had completed a $3.3 billion privatization transaction and officially withdrew from the New York Stock Exchange. The reporter saw in the prospectus that in July and October 2016, Mindray Medical had two capital increase and share expansion. As of the signing date of the prospectus, there were 44 shareholders, Smartco Development and Magnifice were the first and second largest shareholders respectively, with shareholding ratios of 29.89% and 27.14% respectively. It is worth mentioning that as the actual controller of Smartco Development and Magnifice and the founder of Mindray, Li Xiting and Xu Hang also indirectly hold 7.5905% of the company's shares through Ruilong Management and Ruifu Investment. Indirectly held 64.6263% of the company's shares. A Shenzhen-based investment institution with Midi Medical has revealed to reporters that the medical device industry is a strategic emerging industry supported by the state, and there is still huge room for growth in China's medical device market. "There are two important trends in the development of medical devices in China: one is the localization of medical devices, especially high-end medical devices; the other is intelligent, and Mindray, as the largest domestic producer, has strong technical and financial strength." Packing Net or Glass Bottle Net Packing Net,Packaging Nets,Packaging Net,Fruit Packaging Net Changzhou Satidi Import and Export Co., Ltd. , https://www.guanjiejt.com